Navigation Links
Reach2HD, a Phase II study in Huntington's disease, launched
Date:6/7/2012

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) throughout the United States and Australia, "A randomized, double-blind, placebo-controlled, study to assess the safety and tolerability, and efficacy of PBT2 in patients with early to mid-stage Huntington's disease" comparing a 100 mg dose or 250 mg dose versus placebo. The HSG is a not-for-profit group of physicians and other clinical researchers who are experienced in the care of HD patients and dedicated to clinical research of the disease. This trial is sponsored by Prana Biotechnology Limited (Melbourne, Australia) and is being managed by the University of Rochester Medical Center.

Huntington's disease is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia. HD is characterized by brain cell death that usually begins between the ages of 30 to 50, and results in motor, cognitive and behavioral signs and symptoms. While there are medications to help relieve some of the disease symptoms, there is no known treatment to address the cognitive impairment associated with HD.

Research has shown that normally occurring metals in the brain play a significant role in diseases such as Alzheimer's disease and more recently, HD. Researchers at Prana Biotechnology are identifying drugs designed to interrupt interactions between these biological metals and target proteins in the brain, to prevent deterioration of brain cells. One of the chemical compounds, called PBT2, has shown in animal models, and as well as in a small group of patients with Alzheimer's disease, that it may improve cognition. There is some indication in animal models of HD, that the drug may improve motor function and control, increase life span and reduce the amount of brain cell degeneration. Based on these results, Prana is investigating whether the drug will have similar effects with HD patients.

Reach2HD will evaluate how safe and well tolerated PBT2 is at a dose of 100 mg or 250 mg a day compared to a placebo over six months. The trial will also measure whether there is an effect on cognitive abilities as well as other HD symptoms including motor and overall functioning of individuals with HD.

"We are excited to work with Prana to investigate the safety and tolerability of an interesting and innovative experimental treatment for Huntington's disease, PBT2," said Dorsey. "We have few treatment options for Huntington disease, and none for cognition. We hope this is a step to addressing this large unmet need for patients and their families."


'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Study Suggests Vaccine May Help Kids With Brain Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
5. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
6. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
7. No Added Cancer Risk From Hip Replacement Materials: Study
8. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
9. Early Study Finds Some Promise for Lung Cancer Vaccine
10. Narcissists Often Ace Job Interviews, Study Finds
11. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2019)... ... December 05, 2019 , ... Abide, the #1 Christian meditation and ... this year using Bible-based bedtime stories. Listeners have recovered from bad dreams and night ... Center for Disease Control, one third of Americans suffer from poor sleep, which is ...
(Date:12/5/2019)... ... December 05, 2019 , ... Today at M Health Fairview University ... staff member who will to help them take medicine, relax during anxious moments, ... , Rocket, presented by NutriSource® is a golden retriever and the first and ...
(Date:12/4/2019)... ... December 04, 2019 , ... Healthcare Real Estate ... only national awards dedicated to recognizing excellence in the areas of healthcare real ... in nine different categories during the GlobeSt Healthcare Conference today in Scottsdale, Ariz. ...
(Date:12/2/2019)... , ... December 02, 2019 , ... More than $400 ... midnight on December 31. While many people spend their tax-free funds throughout the year, ... on New Year’s Eve. In an effort to help account holders use -- not ...
(Date:11/30/2019)... ... 28, 2019 , ... As American families gather to celebrate Thanksgiving this year, ... of their loved ones. For those with a life-limiting illness, hospice care can provide ... , Spending their final months at home takes on special meaning this time of ...
Breaking Medicine News(10 mins):
(Date:12/5/2019)... (PRWEB) , ... December 05, ... ... announce its entrance into the Amazon Web Services (AWS) Public Sector Partner ... , The Public Sector Partner program recognizes and collaborates with partners that ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex Health, Inc., ... technologies to treat chronic pain in soft and hard tissue, recently achieved a ... , Dr. Bernard Morrey, Chief Medical Officer of Tenex Health, said, ...
(Date:12/2/2019)... ... December 02, 2019 , ... Data integration has been a pharma industry buzzword ... and external data sources, staff are still working in silos and are not aware ... take six weeks or more, and nearly one-third of qualified investigators may be overlooked. ...
Breaking Medicine Technology: